<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02116348</url>
  </required_header>
  <id_info>
    <org_study_id>FWA 000017585</org_study_id>
    <nct_id>NCT02116348</nct_id>
  </id_info>
  <brief_title>Cerebrolysin Neural Repair Therapy in Children With Traumatic Brain Injury and Cerebral Palsy</brief_title>
  <official_title>Effect of Nerve Growth Factor (Cerebrolysin) Therapy on Neurodevelopment, Sleep Pattern and Quality of Life in Children With Traumatic Brain Injury and Cerebral Palsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cerebral palsy (CP) is the most frequent cause of motor handicap among children. The economic
      burden of CP in USA includes $1.18 billion in direct medical costs, $1.05 billion in direct
      non-medical costs, and an additional $9.24 billion in indirect costs, for a total cost of
      $11.5 billion or $921,000 average cost per person. Associated disabilities as mental
      retardation, delayed speech development add psychological burden of the disease on the family
      as well as economic burden.

      Mental retardation is the major problem in children with cerebral palsy. Improving mental
      development will have a positive effect on quality of life for the child and his family.
      Treating associated impairments (mental retardation) with Cerebrolysin will improve mental
      development and quality of life, and will decrease the economic burden in children with
      cerebral palsy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>neurodevelopment</measure>
    <time_frame>6 months</time_frame>
    <description>Intelligence quotient (IQ) assessment at base line and after 3 and 6 month of therapy</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cerebral Palsy Children</condition>
  <condition>Children With Traumatic Brain Injury</condition>
  <condition>Mental Handicap</condition>
  <condition>Delayed Speech Development</condition>
  <arm_group>
    <arm_group_label>Cerebrolysin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nerve growth factor Cerebrolysin will be given to the intervention group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>These children will receive conventional treatment for cerebral palsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cerebrolysin (Nerve growth factor)</intervention_name>
    <description>Cerebrolysin will be given to the intervention group</description>
    <arm_group_label>Cerebrolysin</arm_group_label>
    <other_name>Cerebrolysin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cerebral palsy with mental retardation

          -  Severe perinatal brain insult

        Exclusion Criteria:

          1. Severe growth retardation

          2. Gastrostomy tube feeding

          3. Intractable seizures.

          4. Severe motor handicap and deformities from long standing spasticity.

          5. Congenital malformations.

          6. Suspected inborn error of metabolism.

          7. Suspected inherited neurologic disease.

          8. Children with auditory and visual impairments.

          9. Care giver's refusal to participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sahar M.A. Hassanein, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pediatric Department, Children's Hospital, Faculty of Medicine, Ain Shams University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sahar M.A. Hassanein, MD</last_name>
    <phone>201223183943</phone>
    <email>saharhassanein@med.asu.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pediatric Department, Children's Hospital, Faculty of Medicine, Ain Shams University</name>
      <address>
        <city>Cairo</city>
        <state>Abassia</state>
        <zip>11381</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohsen S Elalfy, MD, PhD</last_name>
      <email>elalfym@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Tarek A. Abdo, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Neveen T. Younis, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Iman AA Elagouza, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shaymaa A Maher, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eman A.M. Medany, M.SC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <link>
    <url>http://med.asu.edu.eg/</url>
    <description>Faculty of Medicine, Ain Shams University</description>
  </link>
  <link>
    <url>http://www.asu.edu.eg/</url>
    <description>Ain Shams University web site</description>
  </link>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2014</study_first_submitted>
  <study_first_submitted_qc>April 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2014</study_first_posted>
  <last_update_submitted>April 15, 2014</last_update_submitted>
  <last_update_submitted_qc>April 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Sahar M.A. Hassanein, MD</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Cerebral palsy children</keyword>
  <keyword>Cerebrolysin</keyword>
  <keyword>Sleep questionnaire</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Bayley III scale</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Paralysis</mesh_term>
    <mesh_term>Cerebral Palsy</mesh_term>
    <mesh_term>Language Development Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitogens</mesh_term>
    <mesh_term>Cerebrolysin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

